The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC.
Fairooz F. Kabbinavar
No relevant relationships to disclose
Nazy Zomorodian
No relevant relationships to disclose
Arie S. Belldegrun
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Steven G. Wong
No relevant relationships to disclose
Adrian Bot
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Thinle Chodon
No relevant relationships to disclose
Begonya Comin-Anduix
No relevant relationships to disclose
Phuong Nguyen
No relevant relationships to disclose
Faraz Khan
No relevant relationships to disclose
Matthew Rettig
No relevant relationships to disclose
Allan J. Pantuck
Consultant or Advisory Role - Kite Pharma (U)
Stock Ownership - Kite Pharma